Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

Development of MicroRNA-146a-Enriched Stem Cell Secretome for Wound-Healing Applications.

Waters R., Subham S., Pacelli S., Modaresi S., Chakravarti AR., Paul A.

Laboratory Study on Chronic Wound, Chronic Inflammation, published in Mol Pharm (2019) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Mol Pharm (2019)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
31398053
PMCID
PMC7260687
DOI
10.1021/acs.molpharmaceut.9b00639
Citations
32

Abstract (original English)

Secretome-based therapies have the potential to become the next generation of viable therapeutic wound repair treatments. However, precise strategies aimed to refine and control the secretome composition are necessary to enhance its therapeutic efficacy and facilitate clinical translation. In this study, we aim to accomplish this by transfecting human adipose-derived stem cells (hASCs) with microRNA-146a, which is a potent regulator of angiogenesis and inflammation. The secretome composition obtained from the transfected hASCs (secretome 146a ) was characterized and compared to nontransfected hASCs secretome to evaluate changes in angiogenic and anti-inflammatory growth factor, cytokine, and miRNA content. In vitro proliferation, migration, and tubular morphogenesis assays using human umbilical vein endothelial cells (HUVECs) were completed to monitor the proangiogenic efficacy of the secretome 146a . Finally, the anti-inflammatory efficacy of the secretome 146a was assessed using HUVECs that were activated to an inflammatory state by IL-1β. The resulting HUVEC gene expression and protein activity of key inflammatory mediators were evaluated before and after secretome treatment. Overall, the secretome 146a contained a greater array and concentration of therapeutic paracrine molecules, which translated into a superior angiogenic and anti-inflammatory efficacy. Therefore, this re

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Adipose TissueCell MovementCell ProliferationCells, CulturedHuman Umbilical Vein Endothelial CellsHumansInterleukin-1betaMicroRNAsNeovascularization, PhysiologicStem Cells

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research